Capricor Therapeutics Inc (NASDAQ: CAPR) kicked off on Tuesday, down -5.23% from the previous trading day, before settling in for the closing price of $9.18. Over the past 52 weeks, CAPR has traded in a range of $3.52-$23.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 345.38%. While this was happening, its average annual earnings per share was recorded 66.96%. With a float of $40.12 million, this company’s outstanding shares have now reached $45.58 million.
Let’s determine the extent of company efficiency that accounts for 160 employees. In terms of profitability, gross margin is 31.55%, operating margin of -191.13%, and the pretax margin is -181.71%.
Capricor Therapeutics Inc (CAPR) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Capricor Therapeutics Inc is 12.16%, while institutional ownership is 38.85%. The most recent insider transaction that took place on Sep 20 ’24, was worth 14,999,998. In this transaction 10% Owner of this company bought 2,798,507 shares at a rate of $5.36, taking the stock ownership to the 7,090,351 shares.
Capricor Therapeutics Inc (CAPR) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 66.96% per share during the next fiscal year.
Capricor Therapeutics Inc (NASDAQ: CAPR) Trading Performance Indicators
Take a look at Capricor Therapeutics Inc’s (CAPR) current performance indicators. Last quarter, stock had a quick ratio of 7.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.20, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach 0.06 in one year’s time.
Technical Analysis of Capricor Therapeutics Inc (CAPR)
Looking closely at Capricor Therapeutics Inc (NASDAQ: CAPR), its last 5-days average volume was 1.55 million, which is a jump from its year-to-date volume of 1.24 million. As of the previous 9 days, the stock’s Stochastic %D was 12.29%. Additionally, its Average True Range was 1.22.
During the past 100 days, Capricor Therapeutics Inc’s (CAPR) raw stochastic average was set at 3.29%, which indicates a significant decrease from 6.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 124.99% in the past 14 days, which was higher than the 97.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.26, while its 200-day Moving Average is $11.77. However, in the short run, Capricor Therapeutics Inc’s stock first resistance to watch stands at $9.53. Second resistance stands at $10.35. The third major resistance level sits at $10.86. If the price goes on to break the first support level at $8.20, it is likely to go to the next support level at $7.69. Now, if the price goes above the second support level, the third support stands at $6.87.
Capricor Therapeutics Inc (NASDAQ: CAPR) Key Stats
The company with the Market Capitalisation of 397.38 million has total of 45,676K Shares Outstanding. Its annual sales at the moment are 22,270 K in contrast with the sum of -40,470 K annual income. Company’s last quarter sales were recorded 11,130 K and last quarter income was -7,120 K.
